Abalone Bio's next generation Functional Antibody Selection Technology (FAST) platform directly selects functional antibody modulators of GPCR and ion channel target proteins. Conventional antibody development, by contrast, first selects for high affinity hits, and then assesses the function of only a small subset. By directly interrogating complete antibody libraries for function, we assess previously overlooked candidates and can identify antibodies that functionally modulate their target in novel ways.
ANTIBODY THERAPEUTICS FOR CANCER, INFLAMMATION, AND PAIN.
Abalone is shifting the paradigm for antibody development, isolating drug candidates directly by their modulating effects on integral membrane proteins. Our drug development programs address unmet needs in oncology, inflammation and pain sensation.
Abalone is an early stage biotech start-up in the San Francisco Bay Area. We are partnering with leading academic labs, targeting G protein-coupled receptors (GPCRs) and ion channels.